CN108892664A - A kind of purposes of amides compound and its synthetic method and treating cancer - Google Patents
A kind of purposes of amides compound and its synthetic method and treating cancer Download PDFInfo
- Publication number
- CN108892664A CN108892664A CN201810709054.3A CN201810709054A CN108892664A CN 108892664 A CN108892664 A CN 108892664A CN 201810709054 A CN201810709054 A CN 201810709054A CN 108892664 A CN108892664 A CN 108892664A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- base
- pharmaceutically acceptable
- compound represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses such as I compound represented of formula or its pharmaceutically acceptable salt,Wherein, R1、R2And R3It is independently selected from H, CH3Or F.The present invention is prepared for Formula I and carries out the Primary Study of pharmacological activity.Listed compound lacks EGFR cell to Exon19 in test example table and L858R/T790M EGFR cell all has good activity, has better choice activity compared to Wild type EGFR cell, and the compounds of this invention is selectively better than AZD9291.It is possible thereby to deduce, the compounds of this invention can be used as cancer treatment drugs and be developed, and may have advantage outstanding especially in non-small cell lung cancer.
Description
Technical field
The present invention relates to a kind of amides compound and its purposes of synthetic method and treating cancer.
Background technique
Lung cancer is that the whole world is most common, the respiratory system malignant tumour that causes death toll most.It counts and reports according to Cancer in China
It accuses, China has 4.29 × 10 in 20156Example lung cancer new cases, 2.81 × 106Example lung cancer death case.Wherein, non-small cell lung
Cancer (NSCLC) accounts for 85% or more of all cases of lung cancer, and the death rate is up to 80%~90%.The drug therapy of non-small cell lung cancer
In, target therapeutic agent can act on tumor tissues more accurately, greatly reduce relative to classical cytotoxic drug
Damage to normal surrounding tissue, not only reduces the incidence of Patient drug's adverse reaction, and it is swollen also to significantly improve resistance
The accuracy of tumor.With the development and propulsion of oncomolecularbiology technology, targeted drug treatment becomes oncology in recent years
One of the research hotspot on boundary.
EGFR (Epidermal Growth Factor Receptor) is epidermal growth factor (EGF) cell Proliferation and letter
Number conduction receptor.EGFR tyrosine kinase inhibitor is the military strategist in ancient China important place of recent anti-tumor drug research and development, is had all over the world perhaps
More transnational medicines is looked forward to or puts into a large amount of manpower financial capacities in the research of new E GFR inhibitor.Currently, EGFR junket ammonia
The inhibitor family of acid kinase develops toward multiple target point, non-reversible type direction.Early stage studies and the reversible EGFR junket of listing
In histidine kinase inhibitor for treating, the drug resistance of drug has caused the concern of people.Patient was controlled to 1 year receiving half a year
After treatment, there are about half patients drug resistance phenomenon occurs.More and more signs show that the more safety for researching and developing new framework types has
The non-reversible type EGFR tyrosine kinase inhibitor of effect has not been allowed to delay.
AZD9291 is AstraZeneca development, and FDA in December, 2015 approval listing, indication is that this product is suitable for previously passing through
There is progression of disease when EGF-R ELISA (EGFR) tyrosine kinase inhibitor (TKI) is treated or after treatment, and passes through
Detection the confirmation Locally Advanced or metastatic lung cancer in non-cellule type (NSCLC) adult patient positive there are EGFR T790M mutation
Treatment.The irreversible EGFR inhibitor of Catastrophic selection, shown in tumor experimental models the phase to EGFR-TKI responsive type and
T790M medicament-resistant mutation is effective, has weak selectivity to Wild type EGFR.AZD9291 has had drug resistance report, AZD9291 at present
Acquired resistance mutation mechanism include：EGFR C797S mutation, FGFR1 amplification, HER2 amplification, cMet amplification or MAPK bypass
Pathway activation, histology change (partially changing into Small Cell Lung Cancer) or compound other gene mutations.
Summary of the invention
The present invention provides a kind of compounds of new construction type, specially as I compound represented of formula or its pharmaceutically
Acceptable salt, ester, stereoisomer, solvated compounds,
Wherein, R1、R2And R3It is independently selected from H, CH3Or F.
It is described as I compound represented of formula is preferably：
The present invention also provides the synthetic method such as I compound represented of formula, synthetic route is：
Its specific synthesis step is：
1) in the presence of an inorganic base, cysteine (compound 1) and 2- (chloromethyl) -4,6- difluoro benzo [d] thiazole
(compound 2), which reacts, generates S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) cysteine containing thioether bond
(compound 3)；
2) under alkaline condition, the amino in compound 3 is protected by (9H- fluorenes -9- base) methylchloroformate, generates N-
(((9H- fluorenes -9- base) methoxyl group) carbonyl)-S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) cysteine (compound
4)；
3) in acid condition, the amino in the carboxyl in compound 4 and isoxazole -4- base amine reacts generation ((3-
(((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -1- (isoxazole -4- base amino) -1- oxopropan -2- formic acid
(9H- fluorenes -9- base) base) carbamate (compound 5)；
4) in a suitable solvent, hydrolysis generation 2- amino -3- (((4,6- occurs under alkaline condition for compound 5
Difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl)-N- (isoxazole -4- base) propionamide (compound 6)；
5) amino in compound 6 generates corresponding amide product with corresponding acyl chloride reaction.
Further, the alkali in the step 1) can be sodium hydroxide, potassium hydroxide, calcium hydroxide, and magnesium hydroxide is excellent
Select sodium hydroxide.
Further, the alkali in the step 2) can be sodium carbonate, sodium bicarbonate, potassium carbonate, saleratus, preferably carbon
Sour sodium.
Further, it can be methanesulfonic acid using acid in the step 3), ethane sulfonic acid, propane sulfonic acid, p-methyl benzenesulfonic acid,
Benzene sulfonic acid, p-nitrophenyl sulfonic acid etc., preferably p-methyl benzenesulfonic acid.
Further, hydrolysis solvent can be piperidines in the step 4), second eyeball, 2,2,2- trifluoroethane -1- alcohol,
It is preferred that piperidines.
The present invention also provides described if I compound represented of formula or its pharmaceutically acceptable salt are as EGFR junket ammonia
The application of acid kinase inhibitor.
The present invention also provides described if I compound represented of formula or its pharmaceutically acceptable salt are in treating cancer medicine
Application in object.The cancer can selected from non-small cell lung cancer, Small Cell Lung Cancer, breast cancer, cancer of pancreas, glioma,
Glioblastoma, oophoroma, cervix cancer, colorectal cancer, melanoma, carcinoma of endometrium, prostate cancer, leukaemia,
Any one of gastric cancer, liver cancer, gastrointestinal stromal tumor, thyroid cancer, acute myelocytic leukemia, nasopharyngeal carcinoma, cholangiocarcinoma.
The present invention also provides a kind of pharmaceutical composition, comprising such as I compound represented of formula and/or its is pharmaceutically acceptable
Salt and one or more pharmaceutically acceptable carriers.
Medicine group can be made with pharmaceutically various typical additives (such as diluent and excipient) in the compound of the present invention
Close object.According to therapeutic purposes, pharmaceutical composition can be made to various types of administration unit dosage forms, as tablet, pill, pulvis,
Liquid, suspension, lotion, granule, capsule, suppository and injection (solution and suspension) etc..
In order to shape the pharmaceutical composition of tablet form, it can be used this field any of and widely used figuration
Agent.For example, carrier, such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, avicel cellulose and silicon
Acid etc.；Adhesive, such as water, ethyl alcohol, propyl alcohol, common syrup, glucose solution, starch solution, penetrating judgment solution, carboxymethyl cellulose
Element, lac, methylcellulose and potassium phosphate, polyvinylpyrrolidone etc.；Disintegrating agent, such as dried starch, mosanom, agar powder and sea
Band powder, sodium bicarbonate, calcium carbonate, the aliphatic ester of polyethylene sorbitan, lauryl sodium sulfate, stearic acid monoglycerides,
Starch and lactose etc.；Disintegration inhibitor, such as white sugar, glycerol tristearate, coconut oil and hydrogenated oil and fat；Adsorption enhancer, such as season
Amine base and lauryl sodium sulfate etc.；Wetting agent, such as glycerol, starch；Adsorbent, such as starch, lactose, kaolin, bentonite
With colloid silicic acid etc.；And lubricant, such as pure talcum, stearate, boric acid powder and polyethylene glycol etc..If necessary
Words can also use common coated material to make tablet as sugar coated tablet, painting gelatin film tablet, enteric coated tablets, film coated tablets, double
Tunic tablet and multilayer tablet.
In order to shape the pharmaceutical composition of pill, it can be used this field any of and widely used inborn nature
Agent, for example, carrier, such as lactose, starch, coconut oil, hardened vegetable oils, kaolin and talcum etc.；Adhesive, such as gum arabic
Powder, Huang write rubber powder, gelatin and ethyl alcohol etc.；Disintegrating agent, such as agar and Kelp Powder.
In order to shape the pharmaceutical composition of suppository form, it can be used this field any known and widely used inborn nature
Agent, for example, polyethylene glycol, coconut oil, higher alcohol, the ester of higher alcohol, gelatin and semi-synthetic glyceride etc..
, can be by solution and suspension liquid disinfectant in order to prepare the pharmaceutical composition of injection form, and it is preferably added suitable chlorine
Change sodium, glucose or glycerol etc. are made and the isotonic injection of blood.When preparing injection, it is possible to use in the art any
Common carrier.For example, water, ethyl alcohol, propylene glycol, the isooctadecanol of ethoxylation, the isooctadecanol and polyethylene of polyoxy
The aliphatic ester etc. of anhydro sorbitol.In addition, common lytic agent, buffer and analgesic etc. can also be added.As needed, exist
During treating schizophrenia, colorant, preservative, fragrance, flavoring agent, sweetening agent and other medicines etc. can also be added.
In the present invention, the medication of the pharmaceutical composition is not particularly limited.Can according to patient age, gender and
Other conditions and symptom select the preparation of various dosage forms to be administered.For example, tablet, pill, solution, suspension, lotion, granule
It is oral administration with capsule；Injection can be administered alone, or (such as glucose solution and amino acid are molten with injection conveying liquid
Liquid) it is mixed into row vein injection, muscle can be carried out with injection merely if necessary, inject in intradermal, subcutaneous or abdomen；Suppository is
It is administered into rectum.
In the present invention, use can be properly selected according to method of administration, patient age, gender and other conditions and symptom
Pharmaceutical quantities.
Specific embodiment
Embodiment 1：3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((thiophene -2- base) formyl ammonia
Base)-N- (isoxazole -4- base) propionamide synthesis
1, the synthesis of S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) cysteine
Cysteine (compound 1) (4.85g, 0.04mol) is dissolved in NaOH (80mL) solution of 2mol/L, is then existed
2- (chloromethyl) -4,6- difluoro benzo [d] thiazole (compound 2) (13.18g, 0.06mol) is added under condition of ice bath, then will
Mixture solution is stirred at room temperature to uniform.PH=5 is adjusted using acetic acid, a large amount of solid precipitatings is generated, then filters and be used in combination
Water washing obtains S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) cysteine (compound 3), 9.74g, yield
80%.1H-NMR(400MHz,CDCl3)δ:1.89(s,1H),2.02(s,1H),2.90(dd,1H),3.15(dd,1H),4.02
(t,1H),4.45(s,2H),7.34(t,1H),7.80(d,1H).13C-NMR(125MHz,CDCl3)δ:30.56,33.43,
56.03,104.03,112.59,137.51,138.68,156.01,158.07,159.06,173.56.LC-MS(ESI,pos,
ion)m/z:305[M+H]。
2, N- (((9H- fluorenes -9- base) methoxyl group) carbonyl)-S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) half Guang
The synthesis of propylhomoserin
Compound 3 (9.74g, 0.032mol) and (9H- fluorenes -9- base) methylchloroformate (8.80g, 00.34mol) are added
To 10% Na2CO3In the mixture of (35mL) aqueous solution and the ethyl alcohol newly distilled (30mL), and reaction is stirred 64 hours.Add
After entering water (80mL), reaction mixture is washed 3 times with ether.Water layer is carefully acidified to pH=3 with HCl, and gained is contained
There is the system of sediment in 4 DEG C of cool overnights, filters and washed with cold water.Obtain sepia solid N- (((9H- fluorenes -9- base) first
Oxygroup) carbonyl)-S- ((4,6- difluoro benzo [d] thiazol-2-yl) methyl) cysteine (compound 4), 11.51g, yield
68.3%.1H-NMR(400MHz,CDCl3)δ:2.89(m,1H),3.14(m,1H),3.95(t,1H),4.42(s,2H),5.15-
5.21(m,3H),5.26(s,1H),7.23(t,2H),7.33(t,3H),7.64(d,2H),7.79(d,1H),7.89(d,2H)
.13C-NMR(125MHz,CDCl3)δ:30.56,32.36,48.95,56.36,66.63,104.03,112.59,120.89,
125.07,126.18,127.52,137.51,138.68,139.81,143.41,156.01,158.07,158.48,159.06,
174.84.LC-MS(ESI,pos,ion)m/z:527[M+H]。
3, ((3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -1- (isoxazole -4- base amino) -1- oxygen
For propane -2- formic acid (9H- fluorenes -9- base) base) synthesis of carbamate
By compound 4 (11.51g, 0.022mol), isoxazole -4- base amine (11.85g, 0.022mol) and p-methyl benzenesulfonic acid
(~0.40g) suspension be placed in equipped with mechanical agitator, in the round-bottomed flask of oil bath and Dean-Stark condenser, will react
Mixture is heated to reflux (150-155 DEG C of internal temperature, 170-180 DEG C of oil bath temperature) 15-18 hours, while being monitored by TLC
Reaction.After the reaction was completed, reactant is cooled to 80 DEG C, methanol (27mL) is slowly added to by dropping funel, after being added dropwise,
It is slowly cooled to room temperature reaction mixture under stiring, the solid being obtained by filtration simultaneously is washed with methanol (45mL), and in 100-
2 hours dry at 120 DEG C, obtaining white solid, ((3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -1- is (different
Oxazole -4- base amino) -1- oxopropan -2- formic acid (9H- fluorenes -9- base) base) carbamate (compound 5), 9.26g, yield
71%.1H-NMR(400MHz,CDCl3)δ:2.90(m,1H),3.15(m,1H),4.02(t,1H),4.49(s,2H),5.10(d,
2H),5.21(s,1H),5.35(t,1H),7.24(t,2H),7.34(t,3H),7.43(d,2H),7.80(d,1H),7.90(d,
2H),8.28(s,1H),9.74(s,1H).13C-NMR(125MHz,CDCl3)δ:30.56,32.17,48.95,53.75,
66.63,104.03,112.59,118.36,120.89,125.07,126.18,127.52,137.51,138.68,139.81,
143.41,151.21,152.81,156.01,158.07,158.48,159.06,168.93.LC-MS(ESI,pos,ion)m/
z:593[M+H]。
4,2- amino -3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl)-N- (isoxazole -4- base) propionyl
The synthesis of amine
Compound 5 (9.26g, 0.016mol) is dissolved in CHCl3In (25.0mL), and be added piperidines (44mL,
0.48mol).Reaction mixture is stirred 24 hours, is evaporated in vacuo and removes volatile matter.Pass through column chromatography (SiO2；DCM/MeOH
=10:1) purified mixture obtains yellowish grease 2- amino -3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl)
Sulfenyl)-N- (isoxazole -4- base) propionamide (compound 6), 4.03g, yield 68%.1H-NMR(400MHz,CDCl3)δ:2.08
(s,1H),2.88(m,1H),3.13(m,1H),3.65(s,1H),4.41(s,2H),4.72(t,1H),7.30(t,1H),7.76
(d,1H),7.90(s,1H),9.90(s,1H).13C-NMR(125MHz,CDCl3)δ:30.56,34.13,53.90,104.03,
112.59,118.36,137.51,138.68,151.21,152.81,156.01,158.07,159.06,169.83.LC-MS
(ESI,pos,ion)m/z:371[M+H]。
5,3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((thiophene -2- base) formamido group)-N-
The synthesis of (isoxazole -4- base) propionamide
Compound 6 (4.03g, 0.011mol) is added in dehydrated alcohol (25.0mL), (thiophene-is then gradually added into
2- yl) formyl chloride (0.017mol), stirring, which is warming up to, reacts reflux.End of reaction after about 6 hours, TLC monitor reaction end.It will
After reaction solution stands cooling, filters, and wash filter cake with a small amount of dehydrated alcohol, obtain white solid product 3- (((4,6- difluoros
Benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((thiophene -2- base) formamido group)-N- (isoxazole -4- base) propionamide,
4.49g, yield 85%.1H-NMR(400MHz,CDCl3)δ:2.88(m,1H),3.12(m,1H),4.69(s,2H),5.09(t,
1H),7.20(t,1H),7.34(td,1H),7.80(dd,1H),7.98(dd,1H),8.17(s,1H),8.30(dd,1H),
8.45(s,1H),9.65(s,1H).13C-NMR(125MHz,CDCl3)δ:30.56,32.17,53.09,104.03,112.59,
118.36,122.93,126.97,128.8,137.51,138.68,142.12,151.21,152.81,156.01,158.07,
159.06,164.38,168.93.LC-MS(ESI,pos,ion)m/z:481[M+H]。
Embodiment 3：3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((5- methyl-thiophene -2-
Base) formamido group)-N- (isoxazole -4- base) propionamide synthesis
Compound 6 (4.03g, 0.011mol) is added in dehydrated alcohol (25.0mL), (5- first is then gradually added into
Base-thiophene -2- base) formyl chloride (0.017mol), stirring, which is warming up to, reacts reflux.End of reaction after about 6 hours, TLC monitoring are anti-
Answer terminal.After reaction solution is stood cooling, filters, and wash filter cake with a small amount of dehydrated alcohol, obtain white solid product 3-
(((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((5- methyl-thiophene -2- base) formamido group)-N- (different evil
Azoles -4- base) propionamide, 4.57g, yield 84%.LC-MS(ESI,pos,ion)m/z:495[M+H].
Embodiment 3：3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((the fluoro- thiophene -2- base of 5-)
Formamido group)-N- (isoxazole -4- base) propionamide synthesis
Compound 6 (4.03g, 0.011mol) is added in dehydrated alcohol (25.0mL), 2- (5- is then gradually added into
Fluoro- thiophene -2- base) chloroacetic chloride (2.93g, 0.017mol), stirring, which is warming up to, reacts reflux.End of reaction after about 6 hours, TLC
Monitor reaction end.It after reaction solution is stood cooling, filters, and wash filter cake with a small amount of dehydrated alcohol, obtains white solid production
Object 3- (((4,6- difluoro benzo [d] thiazol-2-yl) methyl) sulfenyl) -2- ((the fluoro- thiophene -2- base of 5-) formamido group)-N- is (different
Oxazole -4- base) propionamide, 4.88g, yield 89%.LC-MS(ESI,pos,ion)m/z:499[M+H].Test example part：
Test 1：Exon19 lacks EGFR (activation single mutant) cells phosphorylation test
Human pneumonocyte system PC9 (Exon19 lack EGFR) is maintained containing 10% fetal calf serum and 2mM glutamine
In RPMI 1640.Cell is set to have 5%CO2Humidified incubator in 37 DEG C grow.By the sowing of 40 μ L cells, (10000 is thin
Born of the same parents/hole) in growth medium in 384 orifice plate of Coming black transparent bottom, in 5%CO under 37 degree2Middle overnight incubation.Make
Dosage is determined with Echo555 sound wave, and the compound of serial dilution in 100%DMSO is added into cell.It is small that culture plate is further cultured for 2
When, after soft mixed culture medium, 40 μ L lysis buffers are added in each hole.By 384 hole of Greiner black high-bond
Then plate is closed with antibody covering is captured with 3%BSA.Then confining liquid is removed, 15 μ L lysates are transferred to
In 384 orifice plate of Greiner black high-bond, cultivate 2 hours.After softly mixing and cleaning culture plate with PBS, 20 μ L are added
Antibody is detected, is cultivated 2 hours.After softly mixing and cleaning culture plate with PBS, 20 μ L QuantaBlu fluorescence peroxidating are added
Object zymolyte is cultivated 1 hour.20 μ L QuantaBlu stop baths are added in culture plate, 352nm excitation wavelength is being used
Fluorescence is read with the Envision micropore board detector of 460nm launch wavelength.The data input that each compound is obtained is suitable
Software package is to execute curve fitting analysis.Based on this data and by compound concentration needed for calculating 50% effect of acquisition come really
Determine IC50Value.
Test 2：The test of L858R/T790M EGFR (double-mutant) cells phosphorylation
Human pneumonocyte system NCI-H1975 is maintained in the RPMI1640 containing 10% fetal calf serum and 2mM glutamine.
Cell is set to have 5%CO2Humidified incubator in 37 DEG C grow.By 40 μ L cells sowing (10000 cells/well) in Coming
In growth medium in 384 orifice plate of black transparent bottom, in 5%CO under 37 degree2Middle overnight incubation.Use Echo555 sound wave
Determine dosage, the compound of serial dilution in 100%DMSO is added into cell.Culture plate is further cultured for 2 hours, it is soft to be mixed
After base, 40 μ L lysis buffers are added in each hole.384 orifice plate of Greiner black high-bond is covered with capture antibody
Lid, is then closed with 3%BSA.Then confining liquid is removed, 15 μ L lysates are transferred to Greiner black high-bond
In 384 orifice plates, cultivate 2 hours.After softly mixing and cleaning culture plate with PBS, 20 μ L of addition detect antibody, cultivate 2 hours.
After softly mixing and cleaning culture plate with PBS, 20 μ L QuantaBlu fluorescence peroxidase substrates are added, are cultivated 1 hour.
20 μ L QuantaBlu stop baths are added in culture plate, using 352nm excitation wavelength and 460nm launch wavelength
Envision micropore board detector reads fluorescence.The data that each compound obtains are inputted suitable software package to intend to execute curve
Close analysis.IC is determined based on this data and by compound concentration needed for calculating 50% effect of acquisition50Value.
Test 3：The test of Wild type EGFR cells phosphorylation
People's colon cell line LoVo is stored in the RPMI1640 of the fetal calf serum containing 3% removing and 2mM glutamine
In.Cell is set to have 5%CO2Humidified incubator in 37 DEG C grow.By 40 μ L cells sowing (10000 cells/well) in
In growth medium in 384 orifice plate of Corning black transparent bottom, in 5%CO under 37 degree2Middle overnight incubation.It uses
Echo555 sound wave determines dosage, and the compound of serial dilution in 100%DMSO is added to cell.Culture plate is further cultured for 2 hours,
After soft mixed culture medium, 40 μ L lysis buffers are added in each hole.By 384 orifice plate of Greiner black high-bond
With antibody covering is captured, then closed with 3%BSA.Then confining liquid is removed, 15 μ L lysates are transferred to Greiner
In 384 orifice plate of black high-bond, cultivate 2 hours.After softly mixing and cleaning culture plate with PBS, addition 20 μ L detection is anti-
Body is cultivated 2 hours.After softly mixing and cleaning culture plate with PBS, 20 μ L QuantaBlu fluorescence peroxidase bottoms are added
Object is cultivated 1 hour.20 μ L QuantaBlu stop baths are added in culture plate, using 352nm excitation wavelength and
The Envision micropore board detector of 460nm launch wavelength reads fluorescence.The data input that each compound is obtained is suitable soft
Part packet is to execute curve fitting analysis.It is determined based on this data and by compound concentration needed for calculating 50% effect of acquisition
IC50Value.
Experimental result see the table below：
As seen from the above table, listed compound lacks EGFR (activation single mutant) cell and L858R/ to Exon19 in table
T790M EGFR (double-mutant) cell all has good activity, living with better choice compared to Wild type EGFR cell
Property, and the compounds of this invention is selectively better than AZD9291.It is possible thereby to deduce, the compounds of this invention can be used as cancer and control
It treats drug to be developed, may have advantage outstanding especially in non-small cell lung cancer.
Claims (7)
1. such as I compound represented of formula or its pharmaceutically acceptable salt,
Wherein, R1、R2And R3It is independently selected from H, CH3Or F.
2. formula I as described in claim 1, characterized in that be selected from following compound：
3. as described in claim 1 if I compound represented of formula or its pharmaceutically acceptable salt are as EGFR tyrosine-kinase
The application of enzyme inhibitor.
4. as described in claim 1 if I compound represented of formula or its pharmaceutically acceptable salt are in treating cancer drug
Application.
5. as described in claim 1 as the synthesis step of I compound represented of formula is：
6. a kind of pharmaceutical composition, it is characterised in that comprising such as I compound represented of formula and/or its pharmaceutically acceptable salt,
And one or more pharmaceutically acceptable carriers.
7. pharmaceutical composition as claimed in claim 5, it is characterized in that：Pharmaceutical composition be made tablet, pill, pulvis, liquid,
The dosage forms such as suspension, lotion, granule, capsule, suppository or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810709054.3A CN108892664A (en) | 2018-07-02 | 2018-07-02 | A kind of purposes of amides compound and its synthetic method and treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810709054.3A CN108892664A (en) | 2018-07-02 | 2018-07-02 | A kind of purposes of amides compound and its synthetic method and treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108892664A true CN108892664A (en) | 2018-11-27 |
Family
ID=64347198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810709054.3A Pending CN108892664A (en) | 2018-07-02 | 2018-07-02 | A kind of purposes of amides compound and its synthetic method and treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108892664A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006645A (en) * | 2011-09-27 | 2013-04-03 | 华东理工大学 | Application of 2-aminobenzothiazole derivatives being taken as DHODH (dihydroorotate dehydrogenase) inhibitor |
| CN104072493A (en) * | 2014-06-05 | 2014-10-01 | 大连理工大学 | Naphthalimide compound containing 2-mercaptobenzothiazole and triazole heterocycle, preparation method and application thereof |
| CN106749097A (en) * | 2016-12-16 | 2017-05-31 | 温州医科大学 | A kind of aminobenzothiazole analog derivative of 6 chlorine 2 and its preparation method and application |
| CN107849034A (en) * | 2015-06-30 | 2018-03-27 | 达纳－法伯癌症研究所公司 | EGFR inhibitor and its application method |
-
2018
- 2018-07-02 CN CN201810709054.3A patent/CN108892664A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006645A (en) * | 2011-09-27 | 2013-04-03 | 华东理工大学 | Application of 2-aminobenzothiazole derivatives being taken as DHODH (dihydroorotate dehydrogenase) inhibitor |
| CN104072493A (en) * | 2014-06-05 | 2014-10-01 | 大连理工大学 | Naphthalimide compound containing 2-mercaptobenzothiazole and triazole heterocycle, preparation method and application thereof |
| CN107849034A (en) * | 2015-06-30 | 2018-03-27 | 达纳－法伯癌症研究所公司 | EGFR inhibitor and its application method |
| CN106749097A (en) * | 2016-12-16 | 2017-05-31 | 温州医科大学 | A kind of aminobenzothiazole analog derivative of 6 chlorine 2 and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 荣国斌，译: "《波谱数据表——有机化合物的结构解析》", 31 October 2020 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6838796B2 (en) | Methyl / fluoro-pyridinyl-methoxy-substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy-substituted pyridinone-pyridinyl compounds | |
| ES2502941T3 (en) | Method of preparation of dihydroindene amide compounds, pharmaceutical compositions containing said compounds and use as a protein kinase inhibitor | |
| WO2016023422A1 (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
| CA2721371C (en) | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | |
| US9187474B2 (en) | Raf inhibitor compounds | |
| CN105669564B (en) | Carbamide compounds, its preparation method, pharmaceutical composition, intermediate and its application | |
| CN108383836A (en) | Heterocyclyl compounds as mek inhibitor | |
| EP3511327B1 (en) | Tyrosine kinase inhibitor and application thereof | |
| CN105722835B (en) | 3- aryl -5- substitution-isoquinoline-1-ketone compound and their therapy application | |
| US10166201B2 (en) | Substituted hydroxystilbenes and their therapeutic applications | |
| CN102421771B (en) | Pyridinone amide derivatives, preparation methods and medical uses thereof | |
| CN110950842B (en) | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | |
| EP3181554B1 (en) | Quinazoline derivative | |
| CN109890817A (en) | 8- (azetidine -1- base)-[1,2,4] triazol [1,5-a] pyridinyl compounds, its composition and methods for using them | |
| CN105601617A (en) | Orthodiazacycle compounds, and preparation method and application thereof | |
| CN108892664A (en) | A kind of purposes of amides compound and its synthetic method and treating cancer | |
| CN108912115A (en) | It is a kind of for treating the EGFR tyrosine kinase inhibitor of lung cancer | |
| CN108690013A (en) | Ben Bing [d]Thiazole and its application as EGFR inhibitor in treatment of cancer | |
| WO2011143864A1 (en) | Anticancer compounds and preparation methods thereof | |
| CN108570044A (en) | A kind of purposes of amides compound and its synthetic method and treating cancer | |
| CN115141197A (en) | 3-aromatic heterocyclic substituted phenyl derivative and preparation method and application thereof | |
| CN108101889A (en) | Deuterated N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls]-trans -2,4- Pentadienamides | |
| US11000485B2 (en) | Substituted hydroxystilbenes as AhR and Nrf2 modulators and their therapeutic applications | |
| JP2022527279A (en) | Quinoline derivatives and their use for the treatment of cancer | |
| CN102267952B (en) | Quinazoline compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181127 |